2-氨基-7-甲氧基四氢萘盐酸盐 | 3880-78-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 2-氨基-7-甲氧基四氢萘盐酸盐
• 中文别名: 7-甲氧基-1,2,3,4-四氢-2-萘胺盐酸盐
• 英文名称: 2-amino-7-methoxy-1,2,3,4-tetrahydronaphthalene hydrochloride
• 英文别名: 7-Methoxy-1,2,3,4-tetrahydro-(2R)-2-naphthaleneamine hydrochloride；2-Amino-7-methoxytetralin hydrochloride；7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine hydrochloride；7-methoxy-1,2,3,4-tetrahydro-[2]naphthylamine; hydrochloride；(s)-7-methoxy-2-aminotetralin hydrochloride；(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)azanium;chloride
• CAS: 3880-78-2
• 化学式: C₁₁H₁₅NO*ClH
• 分子量: 213.707
• InChiKey: PMBXUCCIODNPGO-UHFFFAOYSA-N

物化性质

• 熔点：
  251-253 °C(Solv: methanol (67-56-1); ethyl ether (60-29-7))

计算性质

• 辛醇/水分配系数(LogP)：
  1.93
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  2-氨基-7-甲氧基四氢萘盐酸盐 在 sodium hydroxide 作用下， 以 甲醇 、 水 、 乙酸乙酯 、 异丙醇 、 甲苯 为溶剂， 反应 0.5h， 生成 (R)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine (S)-mandelate
  参考文献：
  名称：

  Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors

  摘要：

  Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

  DOI：

  10.1021/jm101479y
• 作为产物：
  描述：

  N-苄基-7-甲氧基-1,2,3,4-四氢萘-2-胺 在 Pearlman's catalist 氢气 、 溶剂黄146 、 盐酸 作用下， 以 乙醇 、 乙醚 为溶剂， 以92%的产率得到2-氨基-7-甲氧基四氢萘盐酸盐
  参考文献：
  名称：

  PREPARATION OF AMINOTETRALIN COMPOUNDS

  摘要：

  本发明涉及用于制备具有激酶抑制活性的氨基四氢吡啶化合物的合成过程。该发明还提供了在本发明的过程中有用的合成中间体。

  公开号：

  US20100197924A1

文献信息

• Acetylcholinesterase and carbonic anhydrase inhibitory properties of novel urea and sulfamide derivatives incorporating dopaminergic 2-aminotetralin scaffolds
  作者：Bünyamin Özgeriş、Süleyman Göksu、Leyla Polat Köse、İlhami Gülçin、Ramin Ekhteiari Salmas、Serdar Durdagi、Ferhan Tümer、Claudiu T. Supuran

  DOI：10.1016/j.bmc.2016.04.002

  日期：2016.5

  In the present study a series of urea and sulfamide compounds incorporating the tetralin scaffolds were synthesized and evaluated for their acetylcholinesterase (AChE), human carbonic anhydrase (CA, EC 4.2.1.1) isoenzyme I, and II (hCA I and hCA II) inhibitory properties. The urea and their sulfamide analogs were synthesized from the reactions of 2-aminotetralins with N,N-dimethylcarbamoyl chloride

  在本研究中，合成了一系列结合了四氢萘骨架的尿素和磺酰胺化合物，并评估了它们的乙酰胆碱酯酶（AChE），人碳酸酐酶（CA，EC 4.2.1.1）同工酶I和II（hCA I和hCA II）抑制性特性。由2-氨基四氢萘类与N，N-二甲基氨基甲酰氯和N，N-二甲基氨磺酰氯的反应，然后经BBr 3的O-脱甲基化转化为相应的酚，合成了脲及其磺酰胺类似物。测试了新型尿素和磺酰胺衍生物对hCA I，II和AChE酶的抑制作用。这些衍生物在低纳摩尔范围内表现出优异的抑制作用，对hCA I的Ki值为2.61-3.69nM，对hCA II的Ki值为1.64-2.80nM，对AChE的Ki值为0.45-1.74nM。在计算机技术中，例如，使用原子分子动力学（MD）和分子对接模拟来了解当配体接近目标酶的活性位点时的抑制机理。根据实验和计算结果，鉴定了在稳定酶抑制剂加合物中起作用的关键氨基酸。
• AMINO-TETRALIN DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：——

  公开号：US20030171362A1

  公开（公告）日：2003-09-11

  This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: 1 wherein R 1 , R 2 , R 3 and R 4 are as defined in the specification, or individual isomers, racemic or non-racemic mixtures of isomers, or acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use and preparation as therapeutic drugs.

  本发明涉及一般为毒蕈碱M2/M3受体拮抗剂的化合物，其由式I所代表：其中R1、R2、R3和R4如规范中所定义，或其单体异构体、消旋或非消旋异构体混合物，或其可接受的盐或溶剂合物。该发明还涉及含有这种化合物的药物组合物以及用于其使用和制备作为治疗药物的方法。
• Phenylethanolaminotetralines, a process for their preparation and
  申请人：Sanofi

  公开号：US04707497A1

  公开（公告）日：1987-11-17

  A novel phenylethanolaminotetraline having lipolytic activity of formula ##STR1## wherin X represents hydrogen, halogen, a trifluoromethyl or a lower alkyl group and R represents hydrogen, a lower alkyl group not substituted or substituted by a cycloalkyl group containing 3 to 7 carbon atoms, a hydroxy group, a lower alkoxy, carboxy or lower carbalkoxy group; a cycloalkyl group containing 3 to 7 carbon atoms; or a lower alcanoyl group; or a pharmaceutically acceptable salt thereof; a process for its preparation; and pharmaceutical compositions containing it as active ingredient, useful for the treatment of obesity.

  一种具有脂肪分解活性的苯乙醇胺四环素新型化合物的化学式为##STR1##其中X代表氢、卤素、三氟甲基或低碳基；R代表氢、未取代或取代的含3至7个碳原子的环烷基、羟基、低碳基、羟基低碳基、羧基或低碳基羧基；含3至7个碳原子的环烷基或低碳基酰基；或其药学上可接受的盐；其制备方法；以及含其作为活性成分的药物组成物，用于肥胖症的治疗。
• Amino-tetralin derivatives as muscarinic receptor antagonists
  申请人：——

  公开号：US20040092604A1

  公开（公告）日：2004-05-13

  This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: 1 wherein R 1 , R 2 , R 3 and R 4 are as defined in the specification, or individual isomers, racemic or non-racemic mixtures of isomers, or acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use and preparation as therapeutic drugs.

  本发明涉及一般为肌肉型M2/M3受体拮抗剂的化合物，其由式I所表示：其中R1、R2、R3和R4如规范中所定义，或其个别异构体、外消旋或非外消旋异构体混合物，或其可接受的盐或溶剂化物。本发明进一步涉及含有这种化合物的制药组合物以及将其用作治疗药物的方法和制备方法。
• Process for preparation of 2-aminotetralin derivatives and intermediates thereof
  申请人：Honda Tatsuya

  公开号：US20050153408A1

  公开（公告）日：2005-07-14

  The present invention is to efficiently and simply prepare an optically active 7-substituted-2-aminotetralin with industrial advantage. In the process, a 7-substituted-2-tetralone or its bisulfite adduct is reduced with a microorganism to an optically active 7-substituted-2-tetralol. Then, a sulfonyl group is introduced to the hydroxy group to form an optically active 7-substituted-2-sulfonyloxytetralin. Then, with inversion of the configuration, a nitrogen substituent is introduced using a nitrogen nucleophile to form an optically active 2,7-substituted tetralin. Furthermore, if necessary, the nitrogen substituent is converted into a non-substituted amino group. Thus, an optically active 7-substituted-2-aminotetralin or its salt is prepared.

  本发明旨在以工业优势高效简便地制备光学活性的7-取代-2-氨基四氢萘。在该过程中，使用微生物将7-取代-2-四氢萘酮或其亚硫酸盐加合物还原为光学活性的7-取代-2-四氢萘醇。然后，引入磺酰基到羟基上，以形成光学活性的7-取代-2-磺酰氧基四氢萘。接着，通过构型反演，使用氮亲核试剂引入氮取代基，以形成光学活性的2,7-取代四氢萘。此外，如有必要，氮取代基可转化为非取代的氨基。因此，制备了光学活性的7-取代-2-氨基四氢萘或其盐。